CA2197427A1 - Therapie genique pour transplantation et troubles inflammatoires ou thrombotiques - Google Patents
Therapie genique pour transplantation et troubles inflammatoires ou thrombotiquesInfo
- Publication number
- CA2197427A1 CA2197427A1 CA002197427A CA2197427A CA2197427A1 CA 2197427 A1 CA2197427 A1 CA 2197427A1 CA 002197427 A CA002197427 A CA 002197427A CA 2197427 A CA2197427 A CA 2197427A CA 2197427 A1 CA2197427 A1 CA 2197427A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- thrombomodulin
- dna encoding
- tissue
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 6
- 238000002054 transplantation Methods 0.000 title abstract description 4
- 238000001415 gene therapy Methods 0.000 title description 5
- 230000001732 thrombotic effect Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 103
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000003213 activating effect Effects 0.000 claims abstract description 9
- 230000001413 cellular effect Effects 0.000 claims abstract description 8
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 7
- 102000012607 Thrombomodulin Human genes 0.000 claims abstract 24
- 108010079274 Thrombomodulin Proteins 0.000 claims abstract 24
- 230000005934 immune activation Effects 0.000 claims abstract 2
- 230000001900 immune effect Effects 0.000 claims abstract 2
- 230000006759 inflammatory activation Effects 0.000 claims abstract 2
- 210000004962 mammalian cell Anatomy 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 42
- 210000000056 organ Anatomy 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 24
- 210000001519 tissue Anatomy 0.000 claims description 22
- 230000001177 retroviral effect Effects 0.000 claims description 15
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims description 12
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 9
- 108020004440 Thymidine kinase Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 208000009889 Herpes Simplex Diseases 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 3
- 229940104230 thymidine Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 102000051206 human THBD Human genes 0.000 claims 3
- 238000001727 in vivo Methods 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 41
- 239000013598 vector Substances 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 23
- 239000013612 plasmid Substances 0.000 description 16
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 9
- 108090000190 Thrombin Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 101800004937 Protein C Proteins 0.000 description 8
- 102000017975 Protein C Human genes 0.000 description 8
- 101800001700 Saposin-D Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 229960000856 protein c Drugs 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 229930193140 Neomycin Natural products 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000713869 Moloney murine leukemia virus Species 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 241001045988 Neogene Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 101150091879 neo gene Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101150084279 TM gene Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000002403 aortic endothelial cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940100689 human protein c Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100349268 Caenorhabditis elegans ntr-2 gene Proteins 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000750042 Vini Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Procédé de modification génétique de cellules de mammifères afin de rendre celles-ci moins sensibles à un stimulus inflammatoire ou immunologique, notamment pour diminuer la tendance des cellules endothéliales à provoquer une coagulation lorsque celles-ci sont soumises à une activation inflammatoire ou immune, ce procédé consistant à modifier génétiquement les cellules en insérant dans celles-ci l'ADN codant la thrombomoduline aux fins d'expression de la thrombomoduline fonctionnelle à partir de ces cellules, dans des conditions d'activation cellulaire. On peut effectuer ce procédé, soit in vivo soit in vitro (ex vivo), celui-ci étant indiqué dans une transplantation, de même que dans le traitement d'états systémiques ou inflammatoires locaux caractérisés par la thrombose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US296,945 | 1981-08-28 | ||
| US29694594A | 1994-08-26 | 1994-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2197427A1 true CA2197427A1 (fr) | 1996-03-07 |
Family
ID=23144206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002197427A Abandoned CA2197427A1 (fr) | 1994-08-26 | 1995-08-25 | Therapie genique pour transplantation et troubles inflammatoires ou thrombotiques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0781333A1 (fr) |
| JP (1) | JPH10508187A (fr) |
| AU (1) | AU3518695A (fr) |
| CA (1) | CA2197427A1 (fr) |
| WO (1) | WO1996006933A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US8075880B2 (en) | 1999-01-11 | 2011-12-13 | Steward St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for regulating angiogenesis |
| JP2004503216A (ja) | 2000-05-22 | 2004-02-05 | ジョンズ・ホプキンス・ユニバーシティ | 疾患を阻止するための血管移植片の遺伝子工学処理 |
| US7501114B2 (en) * | 2002-12-02 | 2009-03-10 | Biovec, Llc | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7803365B2 (en) | 2002-12-02 | 2010-09-28 | Biovec, Llc | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| US7470538B2 (en) | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| WO2004076635A2 (fr) * | 2003-02-25 | 2004-09-10 | Biovec B.V. | Applications therapeutiques du gene de la thrombomoduline au moyen de vecteurs viraux et non viraux |
| CA2558510A1 (fr) * | 2004-03-04 | 2005-09-15 | The University Of British Columbia | Haplotypes de la thrombomoduline (thbd) permettant d'etablir un pronostic pour des patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006997A1 (fr) * | 1988-12-13 | 1990-06-28 | United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Cellules endotheliales modifiees par genie genetique et utilisation de ces cellules |
| EP0556345B2 (fr) * | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Vecteurs de retrovirus efficaces en therapie genique |
| AU3968193A (en) * | 1992-03-26 | 1993-10-21 | Gensia, Inc. | In vivo peptide therapy |
| WO1994027612A1 (fr) * | 1993-05-20 | 1994-12-08 | Baylor College Of Medicine | Therapie genetique contre une maladie cardiovasculaire |
| US5645829A (en) * | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| EP0755268A1 (fr) * | 1994-04-11 | 1997-01-29 | Baylor College Of Medicine | Compositions et procedes de therapie genique pour traiter des maladies |
-
1995
- 1995-08-25 EP EP95931935A patent/EP0781333A1/fr not_active Withdrawn
- 1995-08-25 JP JP8508483A patent/JPH10508187A/ja active Pending
- 1995-08-25 WO PCT/EP1995/003379 patent/WO1996006933A1/fr not_active Application Discontinuation
- 1995-08-25 AU AU35186/95A patent/AU3518695A/en not_active Abandoned
- 1995-08-25 CA CA002197427A patent/CA2197427A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3518695A (en) | 1996-03-22 |
| EP0781333A1 (fr) | 1997-07-02 |
| JPH10508187A (ja) | 1998-08-18 |
| WO1996006933A1 (fr) | 1996-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| St Louis et al. | An alternative approach to somatic cell gene therapy. | |
| CA2113089C (fr) | Cellules donneuses universelles | |
| AU727546B2 (en) | Transgenic animals for xenotransplantation with reduced antibody-mediated rejection | |
| WO1992015676A1 (fr) | Therapie genique par les cellules somatiques | |
| US7888321B2 (en) | Production of high levels of transgenic factor IX without gene rescue, and its therapeutic uses | |
| US6100443A (en) | Universal donor cells | |
| JPH03503718A (ja) | 修飾された肝細胞およびその用途 | |
| EP0971724A1 (fr) | Expression du facteur ix humain actif, dans un tissu mammaire d'animal transgenique | |
| EP0807170A1 (fr) | Animaux transgeniques exprimant le facteur viii de coagulation chez l'homme et le facteur de willebrand | |
| CA2197427A1 (fr) | Therapie genique pour transplantation et troubles inflammatoires ou thrombotiques | |
| CA2196311A1 (fr) | Cellules porcines traitees par genie genetique | |
| JPH11503905A (ja) | 移植および炎症または血栓症状態の遺伝子治療 | |
| US5955441A (en) | Genetic inhibition of complement mediated inflammatory response | |
| US6916654B1 (en) | Universal donor cells | |
| Lee et al. | Production of recombinant human von Willebrand factor in the milk of transgenic pigs | |
| EP1379677A2 (fr) | Production de niveaux eleves du facteur transgenique ix sans sauvetage de genes, et ses utilisations therapeutiques | |
| WO1994016065A1 (fr) | Production de cellules destinees a la transplantation et reduisant le rejet du greffon par l'hote, et cellules ainsi obtenues | |
| White et al. | The control of hyperacute rejection by genetic engineering of the donor species | |
| WO1994000560A1 (fr) | Matrice de cellules endotheliales microvasculaires et donneuses universelles | |
| US20040117862A1 (en) | Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses | |
| WO1997012040A1 (fr) | THERAPIE GENIQUE A L'AIDE DE PROTEINES p65 MODIFIEES | |
| CA1341246C (fr) | Therapie genique de cellules somatiques | |
| CA2261183A1 (fr) | Vecteur de transfert adenoviral pour le transport genique d'une sequence d'adn | |
| KR100546819B1 (ko) | 사람 프로유로키나제를 생산하는 형질전환 복제 소 및 이의 생산 방법 | |
| Velander et al. | TRANSGENIC NONHUMAN MAMMALS PRODUCING FIBRINOGEN IN MILKAND METHODS OF PRODUCING FIBRIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |